ResMed (RMD)
(Delayed Data from NYSE)
$272.60 USD
+1.41 (0.52%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $272.60 0.00 (0.00%) 7:54 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, ResMed Inc. has a PEG ratio of 2.06 compared to the Medical - Products industry's PEG ratio of 2.33.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RMD 272.60 +1.41(0.52%)
Will RMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMD
Here's Why ResMed (RMD) is a Strong Growth Stock
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why ResMed (RMD) is a Strong Growth Stock
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Other News for RMD
Is RMD consolidating before a move? NR7 shows up after climbing 0.39%
UBS Keeps Their Buy Rating on Resmed (RMD)
Short bets on S&P 500 Healthcare sector eases in August; MRNA stays most shorted stock
UBS Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
ResMed participates in a conference call with KeyBanc